2023
Effect of Torsemide Versus Furosemide on Symptoms and Quality of Life Among Patients Hospitalized for Heart Failure: The TRANSFORM-HF Randomized Clinical Trial
Greene S, Velazquez E, Anstrom K, Clare R, DeWald T, Psotka M, Ambrosy A, Stevens G, Rommel J, Alexy T, Ketema F, Kim D, Desvigne-Nickens P, Pitt B, Eisenstein E, Mentz R, Investigators O. Effect of Torsemide Versus Furosemide on Symptoms and Quality of Life Among Patients Hospitalized for Heart Failure: The TRANSFORM-HF Randomized Clinical Trial. Circulation 2023, 148: 124-134. PMID: 37212600, PMCID: PMC10524905, DOI: 10.1161/circulationaha.123.064842.Peer-Reviewed Original ResearchConceptsPatient Health Questionnaire-2Prespecified secondary end pointsQuality of lifeEffects of torsemideSecondary end pointsHeart failurePatient-reported outcomesKansas City Cardiomyopathy Questionnaire clinical summary scoreNew York Heart Association classPatient Health Questionnaire-2 scoreEnd pointQuestionnaire-2Loop diuretic agentsLoop diuretic useProportion of patientsBaseline health statusClinical summary scoreEjection fraction phenotypeSignificant differencesDiuretic strategyTorsemide groupCause hospitalizationCause mortalityDiuretic usePrimary therapy
2015
A reappraisal of loop diuretic choice in heart failure patients
Buggey J, Mentz RJ, Pitt B, Eisenstein EL, Anstrom KJ, Velazquez EJ, O'Connor CM. A reappraisal of loop diuretic choice in heart failure patients. American Heart Journal 2015, 169: 323-333. PMID: 25728721, PMCID: PMC4346710, DOI: 10.1016/j.ahj.2014.12.009.Peer-Reviewed Original ResearchConceptsHeart failure patientsHeart failureFailure patientsLoop diureticsNew York Heart Association functional classPlasma brain natriuretic peptide levelsYork Heart Association functional classBrain natriuretic peptide levelsHeart failure severityNatriuretic peptide levelsTranscardiac extractionAldosterone secretionAldosterone systemDiuretic useVentricular functionFurosemide useSymptom managementPharmacologic differencesCardiac fibrosisSurrogate markerMEDLINE searchPeptide levelsControl trialEconomic burdenFurosemide
2010
Fatal myocardial rupture after acute myocardial infarction complicated by heart failure, left ventricular dysfunction, or both: The VALsartan In Acute myocardial iNfarcTion Trial (VALIANT)
Shamshad F, Kenchaiah S, Finn PV, Soler-Soler J, McMurray JJ, Velazquez EJ, Maggioni AP, Califf RM, Swedberg K, Kober L, Belenkov Y, Varshavsky S, Pfeffer MA, Solomon SD, Investigators F. Fatal myocardial rupture after acute myocardial infarction complicated by heart failure, left ventricular dysfunction, or both: The VALsartan In Acute myocardial iNfarcTion Trial (VALIANT). American Heart Journal 2010, 160: 145-151. PMID: 20598985, DOI: 10.1016/j.ahj.2010.02.037.Peer-Reviewed Original ResearchConceptsQ-wave myocardial infarctionMyocardial infarctionMyocardial ruptureClinical end-point committeeHigh-risk myocardial infarctionAcute Myocardial Infarction trialEnd-point committeeNonfatal cardiovascular eventsPresence of hemopericardiumQualifying MIMyocardial Infarction trialHigh-risk patientsGlomerular filtration ratePost-MI patientsAcute myocardial infarctionInferior myocardial infarctionDirect surgical visualizationKillip classCardiovascular eventsDiuretic useOral anticoagulantsVentricular dysfunctionClinical characteristicsFatal complicationHeart failure